BACKGROUND: Connective tissue growth factor (CTGF) has been identified as a key factor in the pathogenesis of diseases with significant fibrosis-related complications such as hepatitis, diabetes and renal transplantation. Increasing evidence shows that CTGF levels in plasma, serum and urine have promising biomarker applicability in these disorders. OBJECTIVE: To present an overview of current knowledge on CTGF in various patient populations and the technical aspects of CTGF measurement by enzyme-linked immunosorbent assay (ELISA). METHOD: We performed a comprehensive literature search by using electronic bibliographic databases. CONCLUSION: CTGF is associated with disease severity parameters and outcome in fibrotic disease and may have diagnostic and prognostic values. However, CTGF ELISA needs standardization.
BACKGROUND:Connective tissue growth factor (CTGF) has been identified as a key factor in the pathogenesis of diseases with significant fibrosis-related complications such as hepatitis, diabetes and renal transplantation. Increasing evidence shows that CTGF levels in plasma, serum and urine have promising biomarker applicability in these disorders. OBJECTIVE: To present an overview of current knowledge on CTGF in various patient populations and the technical aspects of CTGF measurement by enzyme-linked immunosorbent assay (ELISA). METHOD: We performed a comprehensive literature search by using electronic bibliographic databases. CONCLUSION:CTGF is associated with disease severity parameters and outcome in fibrotic disease and may have diagnostic and prognostic values. However, CTGF ELISA needs standardization.
Authors: Izida R Minullina; Nina P Alexeyeva; Sergey V Anisimov; Maxim V Puzanov; Svetlana N Kozlova; Yurii V Sviryaev; Andrey Yu Zaritskey; Eugeniy V Shlyakhto Journal: Cell Cycle Date: 2014-03-11 Impact factor: 4.534
Authors: Bao Tung Pham; Wouter Tobias van Haaften; Dorenda Oosterhuis; Judith Nieken; Inge Anne Maria de Graaf; Peter Olinga Journal: Physiol Rep Date: 2015-04